Effective management of chronic Hepatitis C virus (HCV) infection relies heavily on understanding the precise application of antiviral medications like Sofosbuvir. NINGBO INNO PHARMCHEM CO.,LTD. provides essential insights into Sofosbuvir's dosage guidelines and critical drug interactions, empowering healthcare providers to ensure patient safety and treatment efficacy.

The recommended dosage of Sofosbuvir varies based on the patient's age, HCV genotype, and treatment history. For adults with chronic HCV infection, the standard dose is typically one 400 mg tablet taken orally once daily. For pediatric patients aged 3 years and older, dosage is weight-based, administered either as tablets or oral pellets. It is crucial to adhere strictly to these prescribed dosages to maximize therapeutic benefits and minimize risks.

A critical aspect of Sofosbuvir therapy involves managing potential drug interactions. Sofosbuvir is a substrate for P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Therefore, concomitant use with strong P-gp inducers, such as rifampin and St. John's wort, is not recommended, as these can significantly decrease Sofosbuvir plasma concentrations and reduce its therapeutic effect. Similarly, certain anticonvulsants and antimycobacterials are also contraindicated due to potential interactions. Healthcare providers must consult up-to-date drug interaction databases to identify and avoid such combinations.

Furthermore, patients coinfected with Hepatitis B Virus (HBV) require careful monitoring. Sofosbuvir treatment can lead to HBV reactivation, characterized by an abrupt increase in HBV replication. This reactivation can manifest as hepatitis flares or, in severe cases, lead to liver failure and death. Therefore, pre-treatment screening for HBV infection is mandatory, and coinfected patients must be closely monitored throughout and after Sofosbuvir therapy.

NINGBO INNO PHARMCHEM CO.,LTD. is committed to providing high-quality Sofosbuvir, supported by comprehensive information to facilitate its safe and effective use. We emphasize the importance of prescriber education regarding dosage, drug interactions, and safety warnings to ensure optimal patient care in the fight against Hepatitis C.